This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The individual antibiotics, assessed as antibiotic regimens of one, two, or three antibiotics, were ceftriaxone, doxycycline, metronidazole, cefoxitin, levofloxacin, and ofloxacin. These regimens were compared in pairs and not all together.
Location/setting
USA/out-patient.
Methods

Analytical approach:
The analysis was based on a Markov model with a hypothetical cohort of 18-year-old women. The time horizon of the model was 10 years. The authors stated that a societal perspective was adopted.
Effectiveness data:
The clinical data came from a selection of known, relevant studies, the designs of which were not reported. A key assumption of the model was that the relative risk of PID complications (chronic pelvic pain, infertility, and ectopic pregnancy) was decreased by 1% by the more expensive antibiotic regimen. This assumption was necessary due to the lack of reliable head-to-head studies comparing the efficacy and safety of the regimens. Most of the evidence on PID outcome frequency came from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) trial. Other details on the sources of data or the methods used to aggregate these estimates were not given.
Monetary benefit and utility valuations:
The utility valuations were derived from a study that used Health Utility Index scores assigned by an Institute of Medicine panel.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and were discounted at an annual rate of 3%.
Cost data:
The economic analysis included the cost of the antibiotic regimens (acquisition and treatment of side effects) and management of the following PID-related events: chronic pain, ectopic pregnancy, infertility, and tubo-ovarian abscess.
